• The effectiveness of the Noofen® in children with stable primary arterial hypertension

The effectiveness of the Noofen® in children with stable primary arterial hypertension

SOVREMENNAYA PEDIATRIYA.2016.8(80):94-102; doi 10.15574/SP.2016.80.94 

The effectiveness of the Noofen® in children with stable primary arterial hypertension


Marushko Yu. V., Hyschak T. V.

Shupyk National Medical Academy of Postgraduate Education, Kiev, Ukraine


Objective: to evaluate the efficacy and safety of Noofen® (γ-amino-β-fenil-butyric acid hydrochloride) in treatment of children with stable PH.


Materials and methods. The study involved 45 children 12–17 years old with stable PH, which were divided in two groups. The main therapeutic group included 27 children who received non-pharmacological treatment, Noofen® and enalapril. 18 children of comparison group received the same treatment as the children of the main group, but without adding Noofen.


Results. It was found that the Noofen® in combination with antihypertensive therapy by enalapril in children with PH improves the general condition and the reduction of office blood pressure. Noofen® potentiates the effect of enalapril, speeding term normalization of blood pressure and thus reducing the term antihypertensive therapy. The effectiveness of a combination of non-pharmacological therapy, enalapril and Noofen® in reducing average daily systolic BP in 1.33 times higher compared with the use of non-pharmacological therapy and enalapril without adding Noofen®. Combination therapy with enalapril and Noofen® in children with PH reduces energy expenditure during exercise and restoration of hart's functional reserves. The impact of Noofen® on GABA-ergic structure reduces influence of central nervous system on regulating heart rhythm in children with PH, reduces the activity of stress-realizing system through effects on cortisol levels, promotes the elimination of asthenic-neurotic symptoms, anxiety reduction and normalization of the night sleep.


Concludions. The stable primary hypertension (PH) in children requires complex treatment with non-pharmacological therapy, antihypertensive drugs and correction of adaptation processes in the body.


Key words: children, stable hypertension, antihypertensive therapy, Noofen®.


References

1. Mitiuriaieva IO et al. 2015. Alhorytm likuvannia vehetatyvno-sudynnoi dysfunktsii zahipertenzyvnym typom u ditei. Mezhdunarodnyiy zhurn. pediatrii, akusherstva i ginekol. 8; 1: 58.

2. Korenev NM, Bogmat LF, Nosova EM et al. 2014. Arterialnaya giertenziya u podrostkov: faktoryi stabilizatsii i progressirovaniya. Zdorove rebenka. 3(54): 6—11.

3. Chutko LS et al. 2014. Astenicheskie rasstroystva u detey i ih differentsirovannaya terapIya. Zhurnal nevrologii i psihiatrii im SS Korsakova. 114; 12: 99—103.

4. Berk K, Keyri P. 2005. Analiz dannyih s pomoschyu Microsoft Excel. Per s angl. Moskva, Vilyame: 560.

5. Burchinskiy SG. 2015. Vozmozhnosti kompleksnoy korrektsii regulyatornyih funktsiy tsentralnoy nervnoy sistemyi pri psihosomaticheskoy patologi. Simeyna meditsina. 2: 100—105.

6. Maydannik V.G., Mityuryaeva I.O., Kukhta N.M., Matusova M.O., Borzenko I.O., Kulik G.D., Sidorchuk I.O. 2014. The use of «NOOFEN®100»preparation in the complex sanatorium and resort treatment of vegetative dysfunction affected by respiratory disease in children. Sovremennaya pediatriya. 7: 72—79.

7. Lihodeeva VA, Spasov AA et al. 2010. Vliyanie fenibuta na tserebralnyiy krovotok dezadaptirovannyih plovtsov s raznyimi tipami sistemnoy gemodinamIki. Eksperimentalnaya i klin farmakol. 73; 8: 10—13.

8. Voznyak AV. 2013. Effectiveness of «Noofen®» in the complex treatment of vegetative dysfunction in children. Sovremennaya pediatriya. 6(54): 81—87.

9. Vozniak AV. 2015. Efektyvnist preparatu Noofen v kompleksnomu likuvanni vehetatyvnoi dysfunktsii u ditei. Mezhdunarodnыi zhurnal pedyatryy, akusherstva y hynekolohyy. 8; 1: 117—123.

10. Mitiuriaieva IO, Maidannyk VH, Kukhta NM et al. 2014. Vplyv retsydyvuiuchoi patolohii dykhalnoi systemy na rozvytok vehetatyvnykh dysunktsii u ditei ta efektyvnist yikh korektsii. Mezhdunarodnyiy zhurn pediatrii, akusherstva i ginekol. 6; 1: 91—97.

11. Abramova ON, Darmogray VN, Karaseva YuV et al. 2008. Depressiya sintoksicheskih programm adaptatsii kak osnova razvitii stressa. Vestnik novyih med tehnologiy. HV; 2: 23—25.

12. Maidannk VH, Khaitovych MV, Hlebova LP et al. 2014. Diahnostyka ta likuvannia arterialnoi hipertenzii u ditei ta pidlitkiv. Metodychni rekomendatsii. Mezhdunarodnыi zhurn pedyatryy, akusherstva y hynekolohyy. 6; 1: 109—127.

13. Kaladze NN, Zyukova IB. 2013. State of stress — implemented system in children with arterial hypertension. Sovremennaya pediatriya. 5: 147—150.

14. Kovalenko OIe, Roshchyna LP. 2012.Klinichna otsinka optymizatsii likuvannia vehetatyvnykh porushen u studentiv z vykorystanniam preparatu «Noofen». Ukrainskyi visnyk psykhonevrol. 20; 2(71): 97—100.

15. Kuzminova NV, Sierkova VK. 2009. Vehetatyvni rozlady u patsiientiv iz hipertonichnoiu khvoroboiu: diahnostyka ta medykamentozna korektsiia. Ukr med chasop. 2(70): 37—42.

16. Kuzminova NV. 2015. Diahnostyka ta medykamentozna korektsiia vehetatyvnykh rozladiv u zhinok z arterialnoiu hipertenziieiu v peri- i postmenopauzalni periody. Health of woman. 2: 129—136.

17. Marushko YuV, Hyshchak TV. 2016.Korektsiia astenonevrotychnykh proiaviv u ditei z pervynnoiu arterialnoiu hipertenziieiu na foni pryiomu preparatu noofen. Zdorov’ia dytyny. 3(71): 33-39.

18. Marushko YuV, Hyshchak TV. 2014. Systemni mekhanizmy adaptatsii. Stres u ditei. Monohrafiia. Kyiv-Khmelnytskyi, Pryvatna drukarnia FO-P Storozhuk OV: 140.

19. Marushko YuV, Gischak TV. 2012. Sostoyanie adaptatsii i obmen melatonina u detey s pervichnoy arterialnoy gipertenziey. 16 kongr. pediatrov Rossii s mezhdunar. uch., 24—27 fevralya, 2012, Moskva. Sb materialov. Moskva: 481.

20. Marushko YuV, Hyshchak TV, Zlobinets AS. 2012. Stan adaptatsiinykh hormonalnykh system u ditei z pervynnoiu arterialnoiu hipertenziieiu. Material vosmoi mizhnarodnoi naukovo-praktychnoi konferentsii «Rozvytok naukovykh doslidzhen 2012», 19—21 lystop. 2012 r. Poltava: 22—24.

21. Meerson F3. 1993. Pervichnoe stressornoe povrezhdenie miokarda i aritmicheskaya bolezn serdtsa. Kardiologiya. 4: 50—59.

22. Nagornaya NV, Dubovaya AV, Bordyugova EV. 2013. Psihovegetativnyiy sindrom u detey i vozmozhnyie puti ego korrektsii. Tavricheskiy mediko-biologich vestn. 16; 3: 110—115.

23. Maidannyk VH, Mitiuriaieva IO, Hnyloskurenko HV, Sukhodolska ES. 2016. Novi pidkhody do likuvannia veheto-sudynnoi dysfunktsii z hipertenziieiu. Bukovynskyi med visn. 20; 1(77): 72—78.

24. Tyurenkov IN, Perfilova VN, Sadikova NV, Prokofev II. 2016. No-zavisimyiy mehanizm kardioprotektornogo deystviya fenibuta pri stressornom narushenii sokratitelnoy funktsii serdtsa. Eksperimentalnaya i klin farmakol. 11: 8—11.

25. Nyankovsky SL, Babik IV, Movyak LO. 2014. The drug «Noofen» — the choice of an asthenic syndrome therapy for school age children with an «out of hospital pneumonia» diagnosis. Sovremennaya pediatriya. 6: 39—44.

26. Onovlena ta adaptovana klinichna nastanova, zasnovana na dokazakh «Arterialna hipertenziia». Nakaz MOZ Ukrainy vid 24.05.2012 № 384. K. 2012: 107.

27. Monastyirskiy YuI, Serkova VK, Kuzminova NV, Dombrovskaya YuV. 2007. Opyit primeneniya «Noofena» v lechenii bolnyih neyron-tsirkulyatornoy distoniey. Ukrainskiy terapevt zhurn. 4: 83—86.

28. Kubacheva KK, Velikanova LI, Vorohobina NV, Silnitskiy PA. 2009. Osobennosti funktsionalnogo sostoyaniya nadpochechnikov u yunoshey i molodyih muzhchin s arterialnoy gipertenziey. Arterialnaya gipertenziya. 15; 3: 320—324.

29. Marushko YuV, Hyshchak TV, Lysovets OV, Zlobynets AS. 2012. Osoblyvosti obminu melatoninu i kortyzolu u ditei z pervynnoiu arterialnoiu hipertenziieiu. Zbirnyk nauk pr spivrob NMAPO im PL Shupyka. Kyiv. 21; 3: 289—294.

30. Podolskyi OV, Stebliuk VV. 2014. Riven stresornoho napruzhennia ta otsinka yakosti zhyttia u patsiientiv z arterialnoiu hipertenziieiu. Svit medytsyny ta biolohii. 3: 90—93.

31. Polozhennia pro medyko-pedahohichnyi kontrol za fizychnym vykhovanniam uchniv u zahalnoosvitnikh navchalnykh zakladakh. Nakazom Ministerstva okhorony zdorovia Ukrainy ta Ministerstva osvity i nauky Ukrainy # 518/674 vid 20.07.2009 r. http://news.yurist-online.com/laws/6323/.

32. Protokol diahnostyky ta likuvannia khvorob, shcho kharakteryzuiutsia pidvyshchenym krovianym tyskom u ditei. Nakaz MOZ Ukrainy vid 19.07.2005 #362. Novosti meditsinyi i farmatsii. 2006. 9(191): 2—3.

33. Nagorna NV, Dubova GV, Bordyugova YeV, Muravskaya1 IYu, Kislytsia VN, Burka AA, Muravskaya KV. 2013. Towards improving the quality of life of children with vegetative-vascular dysfunction. Sovremennaya pediatriya. 2: 49—54.

34. Rezoliutsiia X-ho konhresu pediatriv Ukrainy «Aktualni problemy pediatrii» (6—8 zhovtnia 2014 roku, Kyiv). http://pcongress.org.ua/4.html.

35. Rekomendatsii Ukrainskoi asotsiatsii kardiolohiv iz profilaktyky ta likuvannia arterialnoi hipertenzii. Posibnyk do Natsionalnoi prohramy profilaktyky i likuvannia arterialnoi hipertenzii. 5-te vydannia, vypr i dop. 2011. Kyiv, PPVMB: 80.

36. Rekomendatsii Ukrainskoi asotsiatsii kardiolohiv, Ukrainskoi asotsiatsii endokrynnykh khirurhiv, asotsiatsii nefrolohiv Ukrainy z dyferentsiinoi diahnostyky arterialnykh hipertenzii. Arterialnaya gipertenziya. 2014. 3: 64—93.

37. Rudenko VM. 2012. Matematychna statystyka. Navchalnyi posibnyk. Kyiv, Tsentr uchbovoi literatury: 304.

38. Nagornaya NV, Dubovaya AV, Bordyugova EV, Pshenichnaya EV, Muravskaya IYu, Kislitsa VN, Burka AA, Belomerya KV. 2013. Sympathetic-vagal balance in children with vegetative-vascular disfunction and the ways of its correction. Sovremennaya pediatriya. 5: 140—146.

39. Tyurenkov IN, Samotrueva MA, Serezhnikova TK. 2011. GAMK-ergicheskaya sistema i preparatyi GAMK v regulyatsii immunogeneza. Eksperimentalnaya i klin farmakol. 74; 11: 36—42.

40. Ustyantseva IM, Hohlova OI, Dunaeva MP. 2007. Kliniko-metabolicheskie osobennosti techeniya arterialnoy gipertenzii u podrostkov. Politravma. 3: 57—62.

41. Tyurenkov IN, Bagmetova VV, Borodkina LE et al. 2012. Fenibut i ego tsitrat v preduprezhdenii psihonevrologicheskih narusheniy,vyizvannyih hronicheskim stressom — lisheniem paradoksalnoy fazyi sna. Eksperimentalnaya i klin farmakol. 75; 6: 8—13.

42. Khaitovych MV. 2016. HAMK-enerhichna neiroprotektsiia: klinichne zastosuvannia. Liky Ukrainy. 1/2: 33—37.

43. Khaitovych MV. 2002. Porushennia kohnityvnykh funktsii u ditei z vehetatyvnymy dysfunktsiiamy ta yikh korektsiia noofenom. Pediatriia, akusherstvo ta hinekolohiia. 5: 84—86.

44. Khyzhniak O, Mynkov M, Cherevko Y. 2015. Hormonalni predyktory arterialnoi hipertenzii u khlopchykiv-pidlitkiv z ozhyrinniam. Ukrainskyi zhurn dytiachoi endokrynol. 2: 14—22.

45. Nagorna NV, Dubova GV, Bordyugova YeV, Muravskaya IYu, Kislytsia VN, Burka AA, Muravskaya KV. 2012. The efficiency of Noofen in correction of psychoemotional status of children with vegetative-vascular dysfunction. Sovremennaya pediatriya. 7(47): 47—51.

46. Stoyanov AN, Vastyanov RS, Kubareva DA et al. 2012. Effektivnost primeneniya Noofena dlya korrektsii vegetativnih disfunktsiy u podrostkov s tserebralnyimi angiodistoniyami i motornyimi rasstroystvami. UkraYinskiy vIsn psihonevrol. 20; 4: 114-119.

47. 2013 ESH/ESC Guidelines for the management of arterial hypertension The Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertension. 2013. 31: 1281—1357.

48. Tykarski A, Narkiewicz K, Gaciong Z et al. 2015. 2015 guidelines for the management of hypertension. Recommendations of the Polish Society of Hypertension — short version. Kardiol Pol. 73: 676—700. https://doi.org/10.5603/KP.2015.0157; PMid:26304155

49. Fallah Z, Djalalinia S, Qorbani M et al. 2016. A Systematic Review of Studies on Blood Pressure in Iranian Pediatric Population: First Report From the Middle East and North Africa. Iran J Pediatr. 5; 26(2): 4496. https://doi.org/10.5812/ijp.4496

50. Mangena P, Saban S, Hlabyago KE, Rayner B. 2016. An approach to the young hypertensive patient. S Afr Med J. 106(1): 36—38. https://doi.org/10.7196/SAMJ.2016.v106i1.10329; PMid:26933708

51. Bassareo PP, Bassareo V, Iacovidou N, Mercuro G. 2014. Antihypertensive therapy in children: differences in medical approach between the United States and Europe. Curr Med Chem. 21(27): 3121—3131. https://doi.org/10.2174/0929867321666140304093848; PMid:24606510

52. Ash GI, Macdonald HV, Pescatello LS. 2013. Antihypertensive effects of exercise among those with resistant hypertension. Hypertension. 61(1): e1. https://doi.org/10.1161/HYPERTENSIONAHA.111.00126; PMid:23129696

53. Daniels SR. 2016. How to Define Hypertension in Children and Adolescents. Circulation. 26; 133(4): 350—351.

54. Asghari G, Yuzbashian E, Mirmiran P et al. 2016, May 4. Dietary Approaches to Stop Hypertension (DASH) Dietary Pattern Is Associated with Reduced Incidence of Metabolic Syndrome in Children and Adolescents. J Pediatr: pii: S0022-3476(16)30021-X.

55. Lin PH, Yeh WT, Svetkey LP et al. 2013. Dietary intakes consistent with the DASH dietary pattern reduce blood pressure increase with age and risk for stroke in a Chinese population. Asia Pac J Clin Nutr. 22(3): 482—491. PMid:24066367

56. Salehi-Abargouei A, Maghsoudi Z, Shirani F, Azadbakht L. 2013. Effects of dietary approaches to stop hypertension (DASH)-style diet on fatal or nonfatal cardiovascular diseases-incidence: a systematic review and metaanalysis on observational prospective studies. Nutrition. 29; 4: 611-618. https://doi.org/10.1016/j.nut.2012.12.018; PMid:23466047

57. Saneei P, Hashemipour M, Kelishadi R et al. 2013. Effects of recommendations to follow the Dietary Approaches to StopHypertensio (DASH) diet v. usual dietary advice on childhood metabolic syndrome: a randomised cross-over clinical trial. Br J Nutr. 110(12): 2250—2259. https://doi.org/10.1017/S0007114513001724; PMid:23773316

58. Gilbert N, Hage A. 2015. Treatment of arterial hypertension in children and adolescents-Update of therapeutic options. Med Monatsschr Pharm. 38(4): 120—131. PMid:26364380

59. Prodam F, Ricotti R, Agarla V et al. 2013. High-end normal adrenocorticotropic hormone and cortisol levels are associated with specific cardiovascular risk factors in pediatric obesity: a cross-sectional study. BMC Med. 20; 11: 44.

60. Harris KC, Benoit G, Dionne J et al. 2016. Hypertension Canada's 2016 Canadian Hypertension Education Program Guidelines for Blood Pressure Measurement, Diagnosis, and Assessment of Risk of Pediatric Hypertension. Can J Cardiol. 32(5): 589—597. https://doi.org/10.1016/j.cjca.2016.02.075; PMid:27118292

61. Wang TJ, Larson MG, Levy D et al. 2004. Impact of obesity on plasma natriuretic peptide levels. Circulation. 109: 594—600. https://doi.org/10.1161/01.CIR.0000112582.16683.EA; PMid:14769680

62. Chaturvedi S, Lipszyc DH, Licht C et al. 2014. Pharmacological interventions for hypertension in children. Evid Based Child Health. 9(3): 498—580. https://doi.org/10.1002/ebch.1975; https://doi.org/10.1002/ebch.1974; PMid:25236305

63. Reinehr T, Kulle A, Wolters B et al. 2014. Relationships between 24-hour urinary free cortisol concentrations and metabolic syndrome in obese children. J Clin Endocrinol Metab. 99(7): 2391—2399. https://doi.org/10.1210/jc.2013-4398; PMid:24670085

64. Seeman T. 2013. Nonpharmacologic treatment is an indispensable part of antihypertensive therapyin all hypertensive children. Am J Hypertens. 26(12): 1460—1461. https://doi.org/10.1093/ajh/hpt189; PMid:24190928

Confirm the action on the portal med-expert.com.ua:

The information is intended only for healthcare professionals, persons with higher or secondary specialized medical education. Confirm that you are a specialist in the field of healthcare and are familiar with the user agreement.